🇺🇸 ASTRAZENECA PLCAZN
Get ASTRAZENECA PLC filings on Telegram the moment they are published.
Follow ASTRAZENECA PLC on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 6-K — Foreign issuer report
Overview: FDA approved Imfinzi in combination with enfortumab vedotin for muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy, following VOLGA Phase III trial results.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest